FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089832768> ?p ?o ?g. }

• W3089832768 abstract "Abstract Background Chronic hepatitis B (CHB) patients who had exposed to lamivudine (LAM) and telbivudine (LdT) had high risk of developing entecavir (ETV)-resistance after long-term treatment. We aimed to conduct a systematic review and a network meta-analysis on the efficacy and cost-effectiveness on antiviral regimens in CHB patients with ETV-resistance. Data sources We searched PubMed, EMBASE and Web of Science for studies on nucleos(t)ide analogues (NAs) treatment [including tenofovir disoproxil fumarate (TDF)-based rescue therapies, adefovir (ADV)-based rescue therapies and double-dose ETV therapy] in CHB patients with ETV-resistance. The network meta-analysis was conducted for 1-year complete virological response (CVR) and biological response (BR) rates using GeMTC and ADDIS. A cost-effective analysis was conducted to select an economic and effective treatment regimen based on the 1-year CVR rate. Results A total of 6 studies were finally included in this analysis. The antiviral efficacy was estimated. On network meta-analysis, the 1-year CVR rate in ETV-TDF [odds ratio (OR)  = 22.30; 95 % confidence interval (CI): 2.78-241.93], LAM-TDF (OR  = 70.67; 95 % CI: 5.16-1307.45) and TDF (OR  = 16.90; 95 % CI: 2.28-186.30) groups were significantly higher than that in the ETV double-dose group; the 1-year CVR rate in the LAM-TDF group (OR  = 14.82; 95 % CI: 1.03-220.31) was significantly higher than that in the LAM/LdT-ADV group. The 1-year BR rate of ETV-TDF (OR = 28.68; 95 % CI: 1.70-1505.08) and TDF (OR = 21.79; 95 % CI: 1.43-1070.09) therapies were significantly higher than that of ETV double-dose therapy. TDF-based therapies had the highest possibility to achieve the CVR and BR at 1 year, in which LAM-TDF combined therapy was the most effective regimen. The ratio of cost/effectiveness for 1-year treatment was 8 526, 17 649, 20 651 Yuan in the TDF group, TDF-ETV group, and ETV-ADV group, respectively. Conclusions TDF-based combined therapies such as ETV-TDF and LAM-TDF therapies were the first-line treatment if financial condition is allowed." @default.
• W3089832768 created "2020-10-08" @default.
• W3089832768 creator A5003240832 @default.
• W3089832768 creator A5010353663 @default.
• W3089832768 creator A5011302477 @default.
• W3089832768 creator A5012370807 @default.
• W3089832768 creator A5081134218 @default.
• W3089832768 date "2020-12-01" @default.
• W3089832768 modified "2023-09-27" @default.
• W3089832768 title "Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis" @default.
• W3089832768 cites W1771537182 @default.
• W3089832768 cites W1828885195 @default.
• W3089832768 cites W1976104517 @default.
• W3089832768 cites W1988254883 @default.
• W3089832768 cites W1995841201 @default.
• W3089832768 cites W2014837723 @default.
• W3089832768 cites W2025530770 @default.
• W3089832768 cites W2042094643 @default.
• W3089832768 cites W2042329639 @default.
• W3089832768 cites W2042565956 @default.
• W3089832768 cites W2055339444 @default.
• W3089832768 cites W2058376942 @default.
• W3089832768 cites W2067109440 @default.
• W3089832768 cites W2068515544 @default.
• W3089832768 cites W2071476028 @default.
• W3089832768 cites W2076506726 @default.
• W3089832768 cites W2088527445 @default.
• W3089832768 cites W2089598022 @default.
• W3089832768 cites W2090738619 @default.
• W3089832768 cites W2096238612 @default.
• W3089832768 cites W2110109022 @default.
• W3089832768 cites W2117947644 @default.
• W3089832768 cites W2125211506 @default.
• W3089832768 cites W2126362543 @default.
• W3089832768 cites W2138029572 @default.
• W3089832768 cites W2141332320 @default.
• W3089832768 cites W2152342879 @default.
• W3089832768 cites W2473305592 @default.
• W3089832768 cites W2521319515 @default.
• W3089832768 cites W2525080806 @default.
• W3089832768 cites W2528088879 @default.
• W3089832768 cites W2529757630 @default.
• W3089832768 cites W2538847141 @default.
• W3089832768 cites W2589056501 @default.
• W3089832768 cites W2598004730 @default.
• W3089832768 cites W2605785536 @default.
• W3089832768 cites W2616131798 @default.
• W3089832768 cites W2726198038 @default.
• W3089832768 cites W2757028679 @default.
• W3089832768 cites W2759604671 @default.
• W3089832768 cites W2784263503 @default.
• W3089832768 cites W2791839818 @default.
• W3089832768 cites W2883340373 @default.
• W3089832768 cites W2899878314 @default.
• W3089832768 doi "https://doi.org/10.1016/j.hbpd.2020.09.007" @default.
• W3089832768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33051132" @default.
• W3089832768 hasPublicationYear "2020" @default.
• W3089832768 type Work @default.
• W3089832768 sameAs 3089832768 @default.
• W3089832768 citedByCount "0" @default.
• W3089832768 crossrefType "journal-article" @default.
• W3089832768 hasAuthorship W3089832768A5003240832 @default.
• W3089832768 hasAuthorship W3089832768A5010353663 @default.
• W3089832768 hasAuthorship W3089832768A5011302477 @default.
• W3089832768 hasAuthorship W3089832768A5012370807 @default.
• W3089832768 hasAuthorship W3089832768A5081134218 @default.
• W3089832768 hasConcept C126322002 @default.
• W3089832768 hasConcept C156957248 @default.
• W3089832768 hasConcept C159047783 @default.
• W3089832768 hasConcept C2522874641 @default.
• W3089832768 hasConcept C2775940106 @default.
• W3089832768 hasConcept C2776175608 @default.
• W3089832768 hasConcept C2777382497 @default.
• W3089832768 hasConcept C2777410769 @default.
• W3089832768 hasConcept C2777869810 @default.
• W3089832768 hasConcept C2779517838 @default.
• W3089832768 hasConcept C2780593183 @default.
• W3089832768 hasConcept C2781144229 @default.
• W3089832768 hasConcept C2781413609 @default.
• W3089832768 hasConcept C44249647 @default.
• W3089832768 hasConcept C71924100 @default.
• W3089832768 hasConcept C90924648 @default.
• W3089832768 hasConcept C95190672 @default.
• W3089832768 hasConceptScore W3089832768C126322002 @default.
• W3089832768 hasConceptScore W3089832768C156957248 @default.
• W3089832768 hasConceptScore W3089832768C159047783 @default.
• W3089832768 hasConceptScore W3089832768C2522874641 @default.
• W3089832768 hasConceptScore W3089832768C2775940106 @default.
• W3089832768 hasConceptScore W3089832768C2776175608 @default.
• W3089832768 hasConceptScore W3089832768C2777382497 @default.
• W3089832768 hasConceptScore W3089832768C2777410769 @default.
• W3089832768 hasConceptScore W3089832768C2777869810 @default.
• W3089832768 hasConceptScore W3089832768C2779517838 @default.
• W3089832768 hasConceptScore W3089832768C2780593183 @default.
• W3089832768 hasConceptScore W3089832768C2781144229 @default.
• W3089832768 hasConceptScore W3089832768C2781413609 @default.
• W3089832768 hasConceptScore W3089832768C44249647 @default.
• W3089832768 hasConceptScore W3089832768C71924100 @default.
• W3089832768 hasConceptScore W3089832768C90924648 @default.
• W3089832768 hasConceptScore W3089832768C95190672 @default.

• next